Evidence map›Paper›PMID 31807542›Full record

ArticleAnnals of translational medicine2019

Cortistatin exerts antiproliferation and antimigration effects in vascular smooth muscle cells stimulated by Ang II through suppressing ERK1/2, p38 MAPK, JNK and ERK5 signaling pathways.

Ying Wang, Xin Zhang, Lei Gao, Jihe Li, Wenjia Chen, Jinyu Chi, Xiaohui Zhang, Yu Fu, Meng Zhao, Na Liu and 5 more

Open access · diamondAbstract read
In one paragraph

Article in Annals of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Functional cooperation between IKCell proliferation · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Endogenous Vasoactive Peptides and Vascular Aging-Related Diseases.Oxidative medicine and cellular longevity · 2022
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Exploring the Pharmacological Mechanisms ofBioMed research international · 2021
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Ying WangDepartment of Cardiology, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Xin ZhangDepartment of Cardiology, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Lei GaoDepartment of Cardiology, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Jihe LiDepartment of Cardiology, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Wenjia ChenDepartment of Cardiology, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Jinyu ChiDepartment of Cardiology, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Xiaohui ZhangDepartment of Cardiology, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Yu FuDepartment of Cardiology, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Meng ZhaoDepartment of Cardiology, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Na LiuDepartment of Cardiology, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Yang LiDepartment of Cardiology, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Yang XuDepartment of Cardiology, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Kelaier YangDepartment of Endocrine, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Xinhua YinDepartment of Cardiology, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Yue LiuDepartment of Cardiology, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Harbin Medical University · CNFirst Affiliated Hospital of Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVascular remodeling, that contributes to cardiovascular diseases such as hypertension develops by anomalous proliferation and migration of vascular smooth muscle cells (VSMCs). Cortistatin (CST), a newly discovered biological peptide, has been acknowledged for its protective effects against cardiovascular diseases. Whether CST has an inhibitory regulation role in angiotensin II (Ang II)-induced proliferation and migration of VSMCs and what molecular mechanisms may participate in the CST inhibition process are still unknown.

methodsVSMCs were divided into control group, Ang II (10

resultsCompared with control group, Ang II upregulated the expression levels of proliferating cell nuclear antigen (PCNA) and osteopontin (OPN) and downregulated that of α-smooth muscle actin (α-SMA), increased the proliferation rate as shown by CCK8 and VSMC migration as shown by Transwell assay in cultured VSMCs of the Ang II group. Meanwhile, in Ang II-cultured VSMCs, we found activation of extracellular signal-regulated kinase (ERK) 1/2, p38 MAP kinase (p38 MAPK), c-Jun N-terminal kinase (JNK), and ERK5 pathways by western blotting at different time points. However, the proliferation and migration stimulated by Ang II were partly reversed by drug inhibitors of the four pathways, namely, PD98059, SB203580, SP600125 and XMD17-109. When Ang II-stimulated VSMCs were cultured with CST pretreatment, we found that proliferation and migration were greatly suppressed as well as that the ERK1/2, p38 MAPK, JNK and ERK5 pathways were deactivated by CST.

conclusionsThe accumulated data suggest that CST may play a protective role in Ang II-promoted proliferation and migration of VSMCs via inhibiting the mitogen-activated protein kinase (MAPK) family pathways, providing a new orientation of CST in protecting against cardiovascular diseases.

Indexed as

angiotensin II (Ang II)Cortistatin (CST)migrationmitogen-activated protein kinases (MAPK)proliferationvascular smooth muscle cells (VSMCs)

Identifiers

PMID31807542
PMCPMC6861776
OpenAlexW2980592165

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.